Day

August 29, 2019
Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma Research Review Issue 31
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand